enoximone has been researched along with Kidney Diseases in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Basaklar, AC; Bukan, N; Demirogullari, B; Gol, IH; Guclu, MM; Kale, N; Karabulut, R; Ozen, IO; Pampal, A; Poyraz, A | 1 |
| Francis, GS; Tang, WH | 1 |
1 review(s) available for enoximone and Kidney Diseases
| Article | Year |
|---|---|
The year in heart failure.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Cardiac Pacing, Artificial; Cardiography, Impedance; Cardiomyopathy, Dilated; Chronic Disease; Clinical Trials as Topic; Comorbidity; Disease Management; Enoximone; Heart Failure; Hemodynamics; Humans; Kidney Diseases; Natriuretic Peptide, Brain; Natriuretic Peptides; Nitric Oxide; Nitric Oxide Synthase; Pacemaker, Artificial; Phosphodiesterase Inhibitors; Practice Guidelines as Topic; Xanthine Oxidase | 2005 |
1 other study(ies) available for enoximone and Kidney Diseases
| Article | Year |
|---|---|
Apart from the other members of PDE inhibitors' family, enoximone does not enhance renal ischemic reperfusion injury: the effects of enoximone on renal ischemia reperfusion.
Topics: Animals; Enoximone; Kidney Diseases; Male; Phosphodiesterase 3 Inhibitors; Phosphodiesterase Inhibitors; Rats; Rats, Wistar; Reperfusion Injury | 2009 |